Infographic: the future of bioanalysis for biologics development


AI-Enhanced Medicine Pill Concept for Future Healthcare. Pill symbolizing integration of artificial intelligence in the development of future healthcare and advanced treatments

Bioanalysis Zone and Altasciences (Laval, Quebec) conducted a survey to investigate and evaluate the analytical methods, innovative solutions, and technologies currently being used by the bioanalytical community. Our infographic details present-day bioanalytical trends for biologic development, as well as how they might develop in the future.

Here is a summary of some of the results that support ongoing trends in the field of biologic bioanalysis:

Liquid chromatography-mass spectrometry (LC-MS) consistently ranked as the most frequently utilized platform for quantitation of most biologicals. Various other platforms are also commonly used, including ligand binding assays, hybrid LBA/LC-MS methods, and digital polymerase chain reaction (dPCR) for oligonucleotides.

Outsourcing continues to be essential, with numerous advantages, including access to specialized services and the potential to save time.

The survey also examined the role of automation, with about half the respondents (48%) saying that some of their biologic workflows are automated. In addition, it was found that 70% anticipate increased automation.

As the scientific community continues to explore the potential for biologic therapeutics, bioanalytical laboratories will need to adapt and grow to meet the need for more automation and specialized services. Biologic analysis and its evolution are integral to developing therapeutics that address a growing number of diseases. Access the infographic to learn more about the results of this survey.

The future of bioanalysis for biologics development

About Altasciences

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

[Illustrated by Tobias Dumbraveanu]